The impact of a nutritional supplement (Impryl®) on male fertility

SUMMER-trial
## PROTOCOL TITLE
‘The impact of a nutritional supplement (Impryl®) on male fertility’

<table>
<thead>
<tr>
<th><strong>Protocol ID</strong></th>
<th>NL61414.091.17</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Short title</strong></td>
<td>SUMMER-trial (SUppleMent Male fERtility)</td>
</tr>
<tr>
<td><strong>EudraCT number</strong></td>
<td>Not applicable</td>
</tr>
<tr>
<td><strong>Version</strong></td>
<td>2.0</td>
</tr>
<tr>
<td><strong>Date</strong></td>
<td>19th of September 2017</td>
</tr>
<tr>
<td><strong>Coordinating investigator</strong></td>
<td>R.M. Smits, MSc, PhD student <a href="mailto:roos.smits@radboudumc.nl">roos.smits@radboudumc.nl</a></td>
</tr>
<tr>
<td><strong>Project leader</strong></td>
<td>Prof. Dr.D.D.M. Braat, gynaecologist, head of department of Obstetrics and Gynaecology, Radboudumc <a href="mailto:didi.braat@radboudumc.nl">didi.braat@radboudumc.nl</a></td>
</tr>
<tr>
<td><strong>Principal investigator</strong> (in Dutch: hoofdonderzoeker/uitvoerder)</td>
<td>Dr. K. Fleischer, gynaecologist, Radboudumc <a href="mailto:kathrin.fleischer@radboudumc.nl">kathrin.fleischer@radboudumc.nl</a></td>
</tr>
<tr>
<td></td>
<td>Dr. W.L.D.M. Nelen, associate professor, quality of reproductive care, Radboudumc <a href="mailto:willianne.nelen@radboudumc.nl">willianne.nelen@radboudumc.nl</a></td>
</tr>
<tr>
<td><strong>Statistical analyses</strong></td>
<td>Dr. J. in ’t Hout, assistant professor Department for Health Evidence <a href="mailto:Joanna.intHout@radboudumc.nl">Joanna.intHout@radboudumc.nl</a></td>
</tr>
<tr>
<td><strong>Participating centres</strong></td>
<td>Radboudumc</td>
</tr>
<tr>
<td></td>
<td>Slingeland Ziekenhuis</td>
</tr>
<tr>
<td></td>
<td>Canisius-Wilhelmina Ziekenhuis</td>
</tr>
<tr>
<td></td>
<td>Jeroen Bosch Ziekenhuis</td>
</tr>
<tr>
<td></td>
<td>Elisabeth-TweeSteden Ziekenhuis</td>
</tr>
<tr>
<td></td>
<td>Maasziekenhuis Pantein</td>
</tr>
<tr>
<td></td>
<td>Bernhoven Ziekenhuis</td>
</tr>
<tr>
<td></td>
<td>Maxima Medisch Centrum</td>
</tr>
<tr>
<td></td>
<td>Maastricht UMC+</td>
</tr>
</tbody>
</table>
| **Sponsor (in Dutch: verrichter/opdrachtgever)** | **Radboud University Medical Centre**  
|**Department of Obstetrics and Gynaecology**  
|**PO Box 9101 6500HB Nijmegen**  
|**The Netherlands** |
| **Subsidising party (Unrestricted grant)** | **Goodlife Fertility B.V.**  
|**Hollandse Hout 239**  
|**8244 GJ Lelystad** |
| **Independent expert** | **Dr. F.M.J. Martens, urologist, Radboudumc**  
|**frank.martens@radboudumc.nl** |
| **Laboratory sites (Manufacturer of food supplement and placebo)** | **Labomar SRL**  
|**I-31036 Istrana (TV)**  
|**Via N. Sauro 35/I**  
|**Italia** |
| **Pharmacy** | **Not applicable** |
## PROTOCOL SIGNATURE SHEET

<table>
<thead>
<tr>
<th>Name</th>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Head of Department:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prof. Dr. D.D.M. Braat, Reproductive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medicine / Head of Department</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obstetrics and Gynaecology</td>
<td></td>
<td></td>
</tr>
<tr>
<td><a href="mailto:didi.braat@radboudumc.nl">didi.braat@radboudumc.nl</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Principal Investigator:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. K. Fleischer, gynaecologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radboudumc</td>
<td></td>
<td></td>
</tr>
<tr>
<td><a href="mailto:kathrin.fleischer@radboudumc.nl">kathrin.fleischer@radboudumc.nl</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Principal Investigator:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. W.L.D.M. Nelen, associate professor, quality of reproductive care, Radboudumc</td>
<td></td>
<td></td>
</tr>
<tr>
<td><a href="mailto:willianne.nelen@radboudumc.nl">willianne.nelen@radboudumc.nl</a></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
TABLE OF CONTENTS

INTRODUCTION AND RATIONALE ........................................................................................................... 9
OBJECTIVES ............................................................................................................................................... 12
STUDY DESIGN .......................................................................................................................................... 13
1. STUDY POPULATION ............................................................................................................................. 15
   1.1 Population (base) ............................................................................................................................. 15
   1.2 Inclusion criteria ............................................................................................................................... 15
   1.3 Exclusion criteria ............................................................................................................................... 15
   1.4 Sample size calculation .................................................................................................................... 15
2. TREATMENT OF SUBJECTS .................................................................................................................. 17
   2.1 Investigational product/treatment ..................................................................................................... 17
   2.2 Use of co-intervention (if applicable) ............................................................................................... 17
   2.3 Escape medication (if applicable) ..................................................................................................... 17
3. INVESTIGATIONAL PRODUCT ............................................................................................................. 18
   3.1 Name and description of investigational product(s) ......................................................................... 18
   3.2 Summary of findings from non-clinical studies ................................................................................ 17
   3.3 Summary of findings from clinical studies ....................................................................................... 18
   3.4 Summary of known and potential risks and benefits ......................................................................... 18
   3.5 Description and justification of route of administration and dosage ............................................. 19
   3.6 Dosages, dosage modifications and method of administration ....................................................... 19
   3.7 Preparation and labelling of Investigational Medicinal Product .................................................... 19
   3.8 Drug accountability ........................................................................................................................... 19
4. NON-INVESTIGATIONAL PRODUCT .................................................................................................. 21
5. METHODS ............................................................................................................................................. 22
   5.1 Study parameters/endpoints ............................................................................................................. 22
      5.1.1 Main study parameter/endpoint ................................................................................................... 22
      5.1.2 Secondary study parameters/endpoints (if applicable) ............................................................... 22
      5.1.3 Other study parameters (if applicable) ....................................................................................... 22
   5.2 Randomisation, blinding and treatment allocation ........................................................................... 22
   5.3 Study procedures .............................................................................................................................. 24
   5.4 Withdrawal of individual subjects .................................................................................................... 25
   5.5 Follow-up of subjects withdrawn from treatment ............................................................................ 25
   5.6 Premature termination of the study ................................................................................................... 25
6. SAFETY REPORTING ............................................................................................................................ 27
   6.1 Temporary halt for reasons of subject safety .................................................................................... 24
   6.2 AEs, SAEs and SUSARs .................................................................................................................... 27
      6.2.1 Adverse events (AEs) .................................................................................................................. 27
      6.2.2 Serious adverse events (SAEs) .................................................................................................... 27
      6.2.3 Suspected unexpected serious adverse reactions (SUSARs) ..................................................... 28
   6.3 Annual safety report ........................................................................................................................... 29
   6.4 Follow-up of adverse events ............................................................................................................. 29
   6.5 [Data Safety Monitoring Board (DSMB) / Safety Committee] ......................................................... 29
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>STATISTICAL ANALYSIS</td>
<td>30</td>
</tr>
<tr>
<td>7.1</td>
<td>Interim analysis</td>
<td>31</td>
</tr>
<tr>
<td>8</td>
<td>ETHICAL CONSIDERATIONS</td>
<td>32</td>
</tr>
<tr>
<td>8.1</td>
<td>Regulation statement</td>
<td>32</td>
</tr>
<tr>
<td>8.2</td>
<td>Recruitment and consent</td>
<td>32</td>
</tr>
<tr>
<td>8.3</td>
<td>Objection by minors or incapacitated subjects (if applicable)</td>
<td>32</td>
</tr>
<tr>
<td>8.4</td>
<td>Benefits and risks assessment, group relatedness</td>
<td>32</td>
</tr>
<tr>
<td>8.5</td>
<td>Compensation for injury</td>
<td>32</td>
</tr>
<tr>
<td>8.6</td>
<td>Incentives</td>
<td>32</td>
</tr>
<tr>
<td>9</td>
<td>ADMINISTRATIVE ASPECTS, MONITORING AND PUBLICATION</td>
<td>33</td>
</tr>
<tr>
<td>9.1</td>
<td>Handling and storage of data and documents</td>
<td>33</td>
</tr>
<tr>
<td>9.2</td>
<td>Monitoring and Quality Assurance</td>
<td>33</td>
</tr>
<tr>
<td>9.3</td>
<td>Amendments</td>
<td>33</td>
</tr>
<tr>
<td>9.4</td>
<td>Annual progress report</td>
<td>33</td>
</tr>
<tr>
<td>9.5</td>
<td>End of study report</td>
<td>33</td>
</tr>
<tr>
<td>9.6</td>
<td>Public disclosure and publication policy</td>
<td>34</td>
</tr>
<tr>
<td>10</td>
<td>STRUCTURED RISK ANALYSIS</td>
<td>35</td>
</tr>
<tr>
<td>11</td>
<td>REFERENCES</td>
<td>36</td>
</tr>
</tbody>
</table>
### LIST OF ABBREVIATIONS AND RELEVANT DEFINITIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABR</td>
<td>ABR form, General Assessment and Registration form, is the application form that is required for submission to the accredited Ethics Committee (In Dutch, ABR = Algemene Beoordeling en Registratie)</td>
</tr>
<tr>
<td>AE</td>
<td>Adverse Event</td>
</tr>
<tr>
<td>AR</td>
<td>Adverse Reaction</td>
</tr>
<tr>
<td>CA</td>
<td>Competent Authority</td>
</tr>
<tr>
<td>CCMO</td>
<td>Central Committee on Research Involving Human Subjects; in Dutch: Centrale Commissie Mensgebonden Onderzoek</td>
</tr>
<tr>
<td>CV</td>
<td>Curriculum Vitae</td>
</tr>
<tr>
<td>DSMB</td>
<td>Data Safety Monitoring Board</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>EudraCT</td>
<td>European drug regulatory affairs Clinical Trials</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>IB</td>
<td>Investigator’s Brochure</td>
</tr>
<tr>
<td>IC</td>
<td>Informed Consent</td>
</tr>
<tr>
<td>IMP</td>
<td>Investigational Medicinal Product</td>
</tr>
<tr>
<td>IMPD</td>
<td>Investigational Medicinal Product Dossier</td>
</tr>
<tr>
<td>METC</td>
<td>Medical research ethics committee (MREC); in Dutch: medisch ethische toetsing commissie (METC)</td>
</tr>
<tr>
<td>(S)AE</td>
<td>(Serious) Adverse Event</td>
</tr>
<tr>
<td>SPC</td>
<td>Summary of Product Characteristics (in Dutch: officiële productinformatie IB1-tekst)</td>
</tr>
<tr>
<td>Sponsor</td>
<td>The sponsor is the party that commissions the organisation or performance of the research, for example a pharmaceutical company, academic hospital, scientific organisation or investigator. A party that provides funding for a study but does not commission it is not regarded as the sponsor, but referred to as a subsidising party.</td>
</tr>
<tr>
<td>SUSAR</td>
<td>Suspected Unexpected Serious Adverse Reaction</td>
</tr>
<tr>
<td>Wbp</td>
<td>Personal Data Protection Act (in Dutch: Wet Bescherming Persoonsgevens)</td>
</tr>
<tr>
<td>WMO</td>
<td>Medical Research Involving Human Subjects Act (in Dutch: Wet Medisch-wetenschappelijk Onderzoek met Mensen)</td>
</tr>
</tbody>
</table>
SUMMARY

Rationale: Infertility is a worldwide problem and about 10%-15% of all couples will be affected by the inability to have children. In approximately 50% of infertile couples a male factor is involved. In the past decade, the role of oxidative stress on sperm has been researched thoroughly and found to be the problem in 30% to 80% of male infertility cases. Impryl® is a nutritional supplement which works on the metabolic system and regulation of oxidative stress by activating the one carbon cycle and therefore recycling of homocysteine.

Objective: To determine the effectiveness of nutritional supplement Impryl® in men of infertile couples on ongoing pregnancy rate, with or without assisted reproduction technology (ART).

Study design: Multicentre, randomised double blind placebo controlled clinical trial/superiority study.

Study population: All participants in this study are male adults, age 18-50 years, part of a couple that is diagnosed with infertility, unregarded the outcome of semen analysis. The couple will either start or is already started with fertility treatment, i.e. expectative management (EM, duration 6 months), intra-uterine insemination (IUI) with or without ovarian stimulation (mild ovarian hyperstimulation (MOH) or ovulation induction (OI)), either in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment.

Intervention: Impryl® or placebo, with identical appearance one tablet each day for a total duration of 6 months. Intervention has to be consumed for at least 3 consecutive months before using semen for ART. In case of expectative management, patients can start directly to conceive.

Main study parameters/endpoints: The primary outcome is the number of ongoing pregnancies ≥ 12 weeks. Secondary outcomes are change in semen parameters between baseline and 3 months intervention in IUI/IVF/ICSI group, based on (pre-wash) total motile sperm count (TMSC). Furthermore the occurrence of pregnancy, time to pregnancy, number of miscarriages, number of ongoing pregnancies ≥ 20 weeks and live birth rate are documented within the study period. The occurrence of adverse events will be reported.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Couples with infertility will receive standard fertility treatment, i.e. EM or ART. The risks and burden of participating in the trial are small. After a complete diagnostic work-up for infertility, the males will be randomised for use of either Impryl® or placebo. Impryl® is a food supplement already free available throughout Europe, online in the Netherlands. Males need to take study medication one tablet each day for 6 months in total. For this study, we want to measure improvement of semen parameters after at least 3 months use of study medication. Performing a pre-wash TMSC is in Radboudumc standard
procedure when semen is used for IUI or IVF/ICSI. However, at some sites there is only a post-wash TMSC available. Furthermore, in couples with EM performing a TMSC after 3 months is not standard care. We decided not to perform a semen analysis in the EM group due to the fact that improvement in fertility treatment from expectative management is not possible. Participants are required to collect study medication directly at their local hospital or at Radboudumc. At the start of taking study medication the couple is asked to fill in a questionnaire about their baseline characteristics. To assess lifestyle changes during intervention and amount of used study medication, every male will be asked each month (6 times in total) to fill in an online questionnaire. Every couple will receive a final questionnaire, 15 months after inclusion, about the outcome of fertility treatment and occurrence of pregnancy. If a woman of a couple is pregnant there is one extra site visit to have an ultrasound at 12 weeks of pregnancy for determining the primary outcome. In conclusion, the burden and risks associated with participation in this trial can be considered negligible.
INTRODUCTION AND RATIONALE

Infertility is a worldwide problem and about 10%-15% of all couples will be affected by the inability to have children.(1, 2) In approximately 50% of infertile couples a male factor is involved.(3) Male infertility is of multifactorial origin. In the past decade, the role of oxidative stress on sperm has been researched thoroughly and found to be the problem in 30% to 80% of male infertility cases. (4-8)

Reactive oxygen species (ROS) are products of normal cellular metabolism. However, oxidative stress occurs when the ROS production overwhelms the semen’s natural antioxidant defenses and causes cellular damage.(9) Increased oxidative stress is due to environmental and lifestyle factors such as smoking, stress, obesity and nutrition. ROS act by directly altering the sperm DNA and by damaging the sperm membrane and therefore affecting the sperm motility and ability of the spermatozoa to break down the oocyte membrane during fertilization. Men with sperm DNA damage can still have normal seminal parameters, however having a poor chance of natural conception.(10) Antioxidants can provide protection against oxidative stress by neutralizing the free oxygen radicals. Examples of antioxidants already present within seminal plasma are ascorbic acid (Vitamin C), α-tocopherol (Vitamin E), glutathione, amino acids (taurine, hypotaurine), albumin, carnitine, carotenoids, flavenoids, urate and prostasomes. Despite the common association between male infertility and oxidative damage, men are rarely treated or screened for oxidative stress. The latter because of the cost and complexity of testing for DNA damage. A recent Cochrane review suggested that antioxidant supplementation in male infertility might improve the outcomes in assisted reproductive technologies (ART). However, the evidence was rated as low and other clinical studies showed contradictory results with even a negative effect of high doses of antioxidants due to reductive stress as a rebound effect.(11) The clinical data on the effect of oral antioxidants in female infertility are even weaker, which is suggested to be the result of heterogeneity in study designs.(12) Alternatives to the straight oral antioxidants were therefore explored. A suitable alternative is to support the natural antioxidant defenses that are predicted to act within the modulation of the natural cellular homeostasis without generating rebound effects. Studies showed a positive effect of a nutritional supplement Condensyl® supporting DNA methylation patterns.(13, 14) Homocysteine is the end-product of the 1-Carbon cycle (feeding DNA methylation) as well the starting substrate for GSH (the tripeptide glutathione) de novo biosynthesis (feeding reducing power to the antioxidant defenses). Homocysteine is in turn an inhibitor of the methylation process and a powerful pro-oxidant. It has a negative effect on spermatogenesis quality and its concentration in the ejaculate is inversely correlated with fertility outcome.(15, 16) Dattilo et al stated that the ideal supplement should work by favoring homocysteine recycling by restoring the efficiency of the 1-Carbon cycle, therefore ensuring the availability of activated methyl groups for DNA methylation and by supporting GSH synthesis, feeding the intracellular antioxidant system. (17) In the non-randomized pilot studies with Condensyl® there was a significant improvement of DNA fragmentation index and even of the clinical pregnancy rate. However, the quality of these studies for the impact on pregnancy rate is rather low due to the non-
randomized nature and in the study of Dattilo et al. performed in 2014 there was no control group.(13, 15) Impryl® is a nutritional supplement mainly consisting of vitamin B, which works on the metabolic system by activating the one carbon cycle and recycling of homocysteine without the use of any direct strong antioxidants. Compared to Condensyl®, Impryl has the added advantage of the activated forms of folate (methylfolate) and B12 (methylcobalamine) to neutralize the effect of the enzyme variants and is therefore predicted to be more effective. The exact mechanism of action of Impryl® is shown in figure 1, Impryl® provides substrates and co-factors in the GSH synthesis to normalize the redox homeostasis.

In conclusion, it is well known that assisted reproduction technologies are expensive and that male infertility is being responsible for approximately 30% of problems with conception and to be a contributory factor in 50%. (18, 19) The medical and non-medical cost per IVF treatment in the Netherlands is estimated to be between 2.885 and 5.259 euro (€) when being expressed in the year 2015 euro by means of the consumer price index (http://statline.cbs.nl). (20, 21) The medical and non-medical costs per unstimulated and stimulated IUI cycle are respectively 497€ and 1123€ for the year 2015. (22) Therefore, substantial cost savings would be made if the use of relatively inexpensive nutritional supplements would lead to a higher ongoing pregnancy rate, a shorter time to pregnancy or to the use of less expensive, less invasive reproduction techniques.
OBJECTIVES

Primary Objective: To test the hypothesis that the number of ongoing pregnancies (i.e. ≥12
weeks of gestation) will be improved by 7.5% in couples treated with Impryl® for infertility
(IUI, IVF/ICSI or EM setting).

Secondary Objectives: Overall pregnancy rate. Time to pregnancy defined as both the time
between a) start of intervention and reaching ongoing pregnancy, and as b) start of fertility
treatment, or after at least 3 months of expectative management, and reaching ongoing
pregnancy. Change in semen parameters between baseline and 3 months intervention,
based on pre-wash total motile sperm count (TMSC) from the subpopulation from
Radboudumc and sites that deliver a pre-wash TMSC before IUI/IVF/ICSI. Number of
miscarriages defined as a non-vital intra-uterine pregnancy before 16 weeks of gestation.
Number of ongoing pregnancies above ≥ 20 weeks. Live birth rate defined as beyond 24
weeks of gestation, the birth of a living child. Live births will be reported within follow-up time
of 15 months. Furthermore the following adverse events will be reported: gastro-intestinal
problems such as reflux, obstipation, diarrhea, nausea or vomiting, furthermore loss of
appetite, headache, dizziness, pruritus or skin rash.
STUDY DESIGN

A multicentre randomised, double blind placebo controlled, clinical trial for Impryl® administration will be performed in the Department of Gynaecology and/or Reproductive Medicine in both academic and non-academic hospitals in The Netherlands.

The 12 centers participating in the study:

<table>
<thead>
<tr>
<th>Hospital</th>
<th>Principal investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radboudumc, Nijmegen</td>
<td>K. Fleischer</td>
</tr>
<tr>
<td>Slingeland Ziekenhuis, Doetinchem</td>
<td>R.B. Donker</td>
</tr>
<tr>
<td>Canisius-Wilhelmina Ziekenhuis, Nijmegen</td>
<td>C.F. van Heteren</td>
</tr>
<tr>
<td>Jeroen Bosch Ziekenhuis, Den Bosch</td>
<td>J.P de Bruin</td>
</tr>
<tr>
<td>Elisabeth-TweeSteden, Tilburg</td>
<td>J.M.S. Smeenk</td>
</tr>
<tr>
<td>Maasziekenhuis Pantein, Boxmeer</td>
<td>E. Haagen</td>
</tr>
<tr>
<td>Bernhoven Ziekenhuis, Uden</td>
<td>M.P. Hoekstra</td>
</tr>
<tr>
<td>Maxima Medisch Centrum, Veldhoven</td>
<td>J.W.M. Maas</td>
</tr>
<tr>
<td>Maastricht UMC+, Maastricht</td>
<td>R.J.T. van Golde</td>
</tr>
<tr>
<td>Gelre ziekenhuizen, Apeldoorn</td>
<td>M.A.F. Traas</td>
</tr>
<tr>
<td>Nij Geertgen, Elsendorp</td>
<td>M. Schoonenberg</td>
</tr>
<tr>
<td>Rijnstate, Arnhem</td>
<td>A.W. Nap</td>
</tr>
</tbody>
</table>

The duration of the study will be approximately 45 months. A run-in period of 6 months is needed for the study set up. The inclusion period will be 24 months. A period of 15 months is needed for follow-up data collection and report of results. We anticipate on a 50% participation rate; the study will be completed in 3.5 - 4 years. Our study design is summarized in figure 2 and a time line is shown in figure 3.
Figure 2. Flow chart study design

Males of infertile couples  
\( n = 1200 \)

- Expectant management  
  \( n = 200 \)
  - Impryl®  
    \( n = 100 \)
  - Placebo  
    \( n = 100 \)

- IUI  
  \( n = 600 \)
  - Impryl®  
    \( n = 300 \)
  - Placebo  
    \( n = 300 \)

- IVF/ICSI  
  \( n = 400 \)
  - Impryl®  
    \( n = 200 \)
  - Placebo  
    \( n = 200 \)

Figure 3. Time line study (in months)

<table>
<thead>
<tr>
<th>Patient information</th>
<th>Inclusion:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Informed consent</td>
</tr>
<tr>
<td></td>
<td>Semen analysis</td>
</tr>
</tbody>
</table>

0 | 3 | 6 | 15

(0) Start intervention  
- Randomisation  
- Start Impryl®/placebo  
- Start EM  
- Start monthly questionnaire

(3) Start IUI/IVF/ICSI  
- Semen analysis

(6) End of intervention  
- Stop Impryl®/placebo  
- Stop monthly lifestyle questionnaire

(12) End of follow-up  
- Questionnaire ‘outcome of treatment & pregnancy’

If pregnancy occurs at any point in time: stop medication and sonography at 12 weeks of gestation
1. STUDY POPULATION

1.1 Population (base)

The research population will be recruited from couples either presenting for evaluation of started fertility treatment or newly presenting with infertility to a gynaecologist or after successful pregnancy. A recruitment of 1200 male patients is proposed. Participants will be recruited from both tertiary and secondary care hospitals. Expected inclusion period is 24 months, since we expect to enrol around 50 patients per month. With a participation rate of 50%, the recruitment of 1200 males in 24 months is feasible (see 2.3 sample size calculation). Due to the existence of the NVOG Consortium 2.0 structure (Dutch Consortium for Healthcare Evaluation in Obstetrics and Gynaecology) the experience of the participating hospitals in including patients is high, most clinics have an onsite research nurse.

1.2 Inclusion criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

- Couples with failure to conceive for at least 12 months
- Couples starting with EM or 1st/2nd/3rd cycle of IUI (with/without ovarian stimulation) or IVF/ICSI
- Male with age 18-50 years
- Female partner with age 18-43 years
- Willing and able to give informed consent

Exclusion criteria

A potential subject who meets any of the following criteria will be excluded from participation in this study:

- Planned or performed diagnostic testicular biopsy (TESE) or percutaneous epididymal sperm aspiration (PESA)
- Ovulation induction (OI) without IUI
- IVF for an absolute tubal factor
- Embryo-transfers after cryopreservation
- Known chromosomal abnormalities related to infertility
- Known urological abnormality such as a varicocele
- Use of other vitamin supplements

1.3 Sample size calculation

The overall success rate (number of ongoing pregnancies, not specified per cycle) in IVF and ICSI in the Netherlands was respectively 19.8% and 21.5% per cycle in 2015. (23) The number of ongoing pregnancies in IUI is estimated to be around 5 to 13% per cycle and around 18% after three cycles. (24-26) Based on our Radboudumc data, the
pregnancy rate in EM is estimated around 25%.

The overall success rate (number of ongoing pregnancies) of IVF and ICSI in the Netherlands has a variability between clinics of respectively 11.1% and 10.1%.(23) In the Cochrane review ‘antioxidants for male subfertility’ it is stated that: “antioxidants may have increased clinical pregnancy rates (OR 3.43, 95% CI 1.92 to 6.11, \( P < 0.0001 \), 7 RCTs, 522 men, \( I^2 = 0\% \), low quality evidence). This suggests that if the chance of clinical pregnancy following placebo or no treatment is assumed to be 6%, the chance following the use of antioxidants is estimated at between 11% and 28%.”(27) We concluded that with a variability around 10% between Dutch clinics and a possible increase of 5% to 12% according to the Cochrane review, a 7.5% increase in ongoing pregnancies is reasonable and feasible.

The study is designed as a superiority study. Based on the above mentioned data, we expect a 7.5% increase in ongoing pregnancy number when men are treated with Impryl® compared to placebo:

- **EM:** increase from 25% to 32.5%
- **IUI:** increase from 18% to 25.5%
- **IVF/ ICSI:** increase from 20% to 27.5%

The ratio between the 3 fertility treatment groups (EM 1: IUI 3: IVF/ICSI 2) is based on the number of new patients treated at Radboudumc and the sites each year. To detect a difference of 7.5% in ongoing pregnancy above 12 weeks, with two-sided alpha of 5% and a beta of 20% (i.e. 80% power), 550 men will need to be randomised to the intervention arm and 550 men to the control arm (1100 in total). We expect the number of participants lost to follow up to be minimal. However, we have assumed and adjusted for a worst case scenario of a loss to follow-up number of 5% in our sample size calculations. To make sure we can account for drop-outs we have to randomise 1155 patients, we rounded this upwards to 1200 patients. We will allocate 600 patients in both intervention and control arm. Figure 1 shows the distribution of the number of participants for the 3 different types of fertility treatment (EM, IUI and IVF/ICSI).
2. TREATMENT OF SUBJECTS
For the purpose of this study subjects will either be treated with a food supplement (Impryl®) 1 tablet once a day or with a placebo 1 tablet once a day, both for a duration of 6 months. Use of the food supplement or placebo will be stopped earlier when pregnancy is achieved.

2.1 Investigational product/intervention
Impryl® tablets will be produced by Labomar SRL who will also produce an identical looking placebo tablet. Intervention will either start after completing diagnostic work up in new couples or directly when couples were already started with ART treatment. However, treatment with study medication has at least been 3 months before using semen for a new ART procedure. When EM is applied, patients start directly with study medication for a total duration of 6 months.

2.2 Use of co-intervention
All couples will receive our standard care for infertility according to the guidelines of the Dutch Society of Obstetrics and Gynaecology. After diagnostic work up couples will either start with 6 months of EM, IUI, IVF or ICSI. Co-treatment with other vitamins or supplements is prohibited. A wash-out period of 3 months is recommended otherwise patients will be excluded or reported as protocol violation.

2.3 Escape medication
Not applicable
3. INVESTIGATIONAL PRODUCT

Impryl® is a food supplement and is therefore not considered an investigational medicinal product. To assess product quality, we have submitted following documents of both the food supplement and placebo: Summary of Product Characteristics (SPC), Certificates of Analysis (CoA), certificate of Good Manufacturing Practice (GMP) and ISO 9001 form (see documents D2 SPC, D2 CoA, D2 GMP Labomar SRL and D2 ISO 9001 Labomar SRL).

3.1 Name and description of investigational product(s)

Impryl®. Tablets of ovoid shape sized 20x8 mm, white color, smooth surface, weight 1300 milligram with active ingredients: microcrystalline cellulose, betaine hydrochloride, L-cysteine, mono and diglycerides of fatty acids, magnesium stearate, disilicio dioxide, zinc bisglycinate, croscarmellose sodium, niacin (nicotinamide), vitamin B6 (pyridoxine hydrochloride), vitamin B2 (riboflavin), folic acid [(6S) -5-methyltetrahydrofolate acid, glucosamine salt], vitamin B12 (cobalamin).

Placebo tablet of identical appearance produced by Labomar SRL.

List of ingredients of placebo (composition):

<table>
<thead>
<tr>
<th>E num.</th>
<th>Common name</th>
<th>Grams per dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>E 460</td>
<td>Cellulose</td>
<td>0,852</td>
</tr>
<tr>
<td>E 341</td>
<td>Calcium phosphates</td>
<td>0,300</td>
</tr>
<tr>
<td>E 172</td>
<td>Iron oxides</td>
<td>0,024</td>
</tr>
<tr>
<td>E 551</td>
<td>Silicon dioxide</td>
<td>0,012</td>
</tr>
<tr>
<td>E 470b</td>
<td>Magnesium salts of fatty acids</td>
<td>0,012</td>
</tr>
</tbody>
</table>

3.2 Summary of findings from (non-) clinical studies

To date no (non-)clinical research with a primary focus on increasing the ongoing pregnancy number by Impryl® has been performed. There is evidence that Impryl® reduces oxidative stress and DNA damage, this is based on research performed with the previous version of the supplement (Condensyl®) in humans.(13)

3.3 Summary of known and potential risks and benefits

There is substantial evidence that supplementation with the precursor of Impryl®, named Condensyl®, is safe and of beneficial in case of absolute (low content in the diet) or relative (increased demand) deficiency.(17) These deficiencies may associate to altered homocysteine metabolism and other disturbances to the defense against oxidative aggressions and are often observed in men and women with reproductive problems. It is to be noted that disturbances of homocysteine metabolism and of oxidative defenses may occur more frequently in subjects carrying a defective genetic variant of one of the main enzymes of homocysteine metabolism including those denominated ethyltetrahydrofolate reductase (MTHFR), methionine transferase reductase (MTRR), Betaine Homocysteine Methyl Transferase (BHMT) and cystathionine beta synthase (CBS).(13) Impryl® has been formulated so to compensate these defects by providing an already activated
substrate (i.e. methylfolate for MTHFR and methyl cobalamin for MTRR), or by providing an excess of substrate (i.e. betaine for BHMT) or by delivering a ready substrate for downstream to the genetic blockade (i.e. cystine for CBS). Thus, Impryl® will deliver an effective dietary support to everybody independently of their genetic substrate for the mentioned enzymes.

Impryl is safe by administering only essential micronutrients that are usually occurring in food, supplied according the recommended daily dose. There are no major warning, there are no reports on side effects or allergies, it is gluten- and lactose free.

3.4 Description and justification of route of administration and dosage

The route of administration of both Impryl® and placebo is by oral intake with a small amount of water, preferentially without food. The recommended daily dose is 1 tablet per day. The assumption of a smaller amount does not guarantee full coverage of the daily need in all subjects. The recommended daily dose should not be exceeded.

3.5 Dosages, dosage modifications and method of administration

All subjects will receive the same dosage of 1 tablet (1.3 gram) taken between meals once a day. No dosage modifications are possible. The medication will be taken orally.

3.6 Preparation and labelling of Investigational Medicinal Product

Manufacturing, preparation, labelling and packaging of both the active verum (Impryl®) and placebo tablets will be performed by Labomar SRL compliant with EU GMP. The labels will be in Dutch. A flaglabel (to be teared off) is used to identify placebo and Impryl®. Distribution of study medication will be organised by either the Radboudumc, department of Reproductive Medicine, or at the local department of Gynaecology at every site. Every centre was given the option to perform randomisation and distribute the study medication at their own hospital or asking their included patients to collect study medication after randomisation at Radboudumc at the above mentioned department.

3.7 Drug storage accountability

The coding and distribution to the trial will be organised by Labomar SRL in collaboration with the principal and coordinating investigators of the Radboudumc. The study medication has to be stored in a dry place at room temperature. No special precautions have to be taken into account. Patients are not asked to return study medication. Since it is a supplement and not medication there are no specials precautions for destruction or disposal.

Drug accountability will be performed in line with GCP requirements. The investigator is responsible for drug accountability and these tasks will be delegated to the primary investigators at the sites. We will log all dispensing of the investigational product on a drug
accountability log. See paragraph 5.2 of this protocol for further details on the dispensing and logging.
4. NON-INVESTIGATIONAL PRODUCT

Not applicable
5. METHODS

5.1 Study parameters/endpoints

5.1.1 Main study parameter/endpoint
Number of ongoing pregnancies, conceived in the time window between month 3 to month 6 of intervention, defined as a visible embryonic heartbeat at ultrasound from 12 weeks of gestation onwards.

5.1.2 Secondary study parameters/endpoints
Overall number of pregnancies
Time to pregnancy defined as
   a) the time between start intervention and reaching ongoing pregnancy
   b) the time between start of fertility treatment (EM, IUI, IVF/ICSI), or after at least 3 months of expectative management, and reaching ongoing pregnancy
Change in semen parameters in IUI/IVF/ICSI group based on pre-wash total motile sperm count (TMSC) from a subpopulation of patients: Radboudumc patients and patients from other sites having pre-wash TMSC as standard procedure when semen is used for IUI or IVF/ICSI.
Number of miscarriages (defined as non-vital intra-uterine pregnancy before 16 weeks of gestation)
Number of ongoing pregnancy ≥20 weeks of gestation
Live birth rate (beyond 24 weeks, defined as the birth of a living child) within study-period of 15 months
Adverse effects

5.1.3 Other study parameters
Baseline parameters are age, length, weight, ethnicity, alcohol/drugs/nicotine use, use of vitamins/steroids or other supplements, diet specifics (normal, vegetarian, vegan, gluten-free, dairy free, other), medication use, activities that cause increased scrotal temperature such as often visiting a sauna, taking a hot bath or race cycling, general health, operations or trauma in genital area, exposure to toxins in environment, conception of previous children, duration of infertility and type of diagnosis of infertility. Furthermore the age and parity of the female partner has to be documented, as well as the occurrence of endometriosis or anovulation.

5.2 Randomisation, blinding and treatment allocation
RANDOMISATION AND TREATMENT ALLOCATION: All couples visiting a fertility specialist for the first time or for evaluation of fertility treatment will be informed on this study. Prior to or at their actual appointment they will receive the patient information (PIF). Randomisation will be performed, after signed informed consent
has been obtained, using a web-based application (Castor). We will use permuted
block-design, stratified for fertility treatment (1st) and recruiting centre (2nd). Block
sizes are flexible. Participants will be randomised in a 1:1 ratio to study medication
(Impryl®) or placebo. Assignment to medication, using the randomisation list, will
either performed at the local centre or at Radboudumc by an independent person.
This person is neither participating in clinical treatment nor processing the study
data. Randomisation outcome is either A (Impryl®) or B (placebo).
CODING: coding starts immediately after informed consent has been obtained. In
Castor each patient will receive a combination of one letter and 3 numbers. The
code will be assigned as followed: Radboudumc (A), Slingeland (B), Canisius-
Wilhelmina (C), Jeroen Bosch (D), Elisabeth-TweeSteden (E), Maasziekenhuis
Pantein (F), Bernhoven (G), Maxima Medisch Centrum (H), Maastricht UMC+ (I),
Gelre ziekenhuizen (J), Nij Geertgen (K) and Rijnstate (L). For example, the first
patient included in Radboudumc will receive the code A001. The code will not
provide any information about the received intervention (Impryl® or placebo). The
list of codes corresponding with patient information and received medication will be
saved in an separate file, locked (either digital with password or a locked cabinet),
only accessible for the independent person who did the randomisation.
BLINDING: The study is double blinded. All personnel, the researchers and patients
will remain blinded to the intervention being received, except the personnel
performing randomisation and distributing the study medication.
DEBLINDING: The indications for breaking the randomisation code are: SAE, SAR
and SUSAR, as instructed by METC, or in a dire emergency, as directed by the
principal investigators or trial manager. Every site has access to a deblinding form
(“Formulier verbreken randomisatie code”) in which patients details, reason for
deblinding, statement of principal site investigator, date and time of intervention stop
and randomisation allocation will be reported. The principal site investigator will
inform the coordinating investigator about the deblinding.
DISTRIBUTION: In Radboudumc and at the local study sites the person distributing
the study medication is an unblinded employee of the department of Reproductive
medicine or Gynaecology who is not involved in the treatment of the patient nor
involved in the data collecting of the research. Every study site can decide to
perform randomisation and distribution of medication at local site or at Radboudumc.
On every distributing study site there will be a batch of study medication stored at
room temperature, no special precautions. An unblinded authorized employee of the
department of Reproductive medicine (or Gynaecology) will distribute the study
medication after randomisation has been performed by Castor. The flag label
(identification A = Impryl® or B = placebo) will be removed from the box, the
randomisation number noted (handwritten) on the medication box, which will then be
handed over to the patient. On the patient identification & drug accountability log
(either digital or on paper) the following details will be reported: date of issue, study
(randomisation) number, batch number, expiration date, amount dispensed, current
storage amount, randomizer/distributor initials, hospital number, patient name and initials, date of birth and monitoring check.

All unblinded personnel performing randomisation will be trained by a site initiation to perform randomisation in Castor EDC and distribution of medication. A log list of all personnel involved in the study, with blinding status, responsibilities and signature, will be saved.

Unblinding will be performed when the study has ended, database is locked and protocol violators have been defined.

5.3 Study procedures

Couples matching the inclusion criteria will be asked to participate in the trial. If after diagnostic work up the diagnosis infertility for the couple remains, both are asked for informed consent. After signing informed consent, the male patient will be randomised and allocated to Impryl® or placebo (double blinded).

Medication

When fertility treatment is expectative management for a period of 6 months, patients can directly start using the food supplement or placebo. Patients can (re)start with fertility treatment (IUI, IVF, ICSI) three months thereafter. The female partner is allowed to start hormonal treatment sooner, however the production of semen for the IUI/IVF/ICSI procedure has to be after at least 3 months of treatment with study medication. Impryl® or placebo will be taken for a total duration of 6 months and will be directly stopped after having a positive pregnancy test.

Baseline characteristics

Patients are asked to report on these characteristics by a short questionnaire. Patients will receive an automatic email invitation directly after randomisation and are asked to provide this information online in the Castor database system.

Lifestyle and outcome characteristics

Patients will be asked once every month to report on occurrence of pregnancy (with date of positive test), changes in weight and diet, changes in habit of smoking and drug or alcohol use, occurrence of fever and change in activities increasing scrotal temperature (hot baths, sauna, race cycling). Furthermore patients are instructed about taking note of the total amount of consumed study medication (used boxes and tablets). There is a question about the occurrence of adverse events. Patients will receive an automatic email and are asked to provide this information online in the Castor database system.

Semen analysis
Semen analysis will be performed two times: once during diagnostic work-up (standard care) and once more after 3 months of using study medication. In Radboudumc and several sites, a pre-wash TMSC is standard care when performing an insemination (IUI group) and will be performed on the semen produced for IVF/ICSI as part of routine measurement before procedure. We decided not to perform a semen analysis in the EM group due to the fact that improvement in fertility treatment from expectative management is not possible. At intake they already have normal semen parameters and the burden of an extra visit is high.

**Transvaginal ultrasonography**
If there is a clinical pregnancy, a routine (standard care) ultrasound will be performed in the first trimester between 5 to 9 weeks to determine the viability. An extra ultrasound will be performed at 12 weeks of pregnancy to determine the number of ongoing pregnancies.

**Questionnaire pregnancy/treatment outcome**
To allow follow-up for treatment and pregnancy outcome, all couples will receive an automatic email with invitation for a short questionnaire 15 months after inclusion. They will receive questions about fertility treatment and pregnancy outcome (ability to achieve a pregnancy, occurrence of miscarriage or childbirth, date of delivery, gestational age, mode of delivery, complications of delivery, birth weight and sex of neonate). An email will be sent if the questionnaire is not returned after one month. If there is no reaction to the reminder email, either the patient or his general practitioner will be contacted by telephone to answer follow-up questions.

### 5.4 Withdrawal of individual subjects

Subjects can leave the study at any time for any reason if they wish to do so without any consequences. The investigator can decide to withdraw a subject from the study for urgent medical reasons. There are no specific criteria for withdrawal.

### 5.5 Follow-up of subjects withdrawn from treatment

As the statistical analysis is planned according to intention to treat principle, patients that violate the study protocol will be analysed in the group that they were allocated to. All patients will receive full follow-up.

### 5.6 Premature termination of the study

The principle investigator at the initiating centre Radboudumc, may temporarily or permanently discontinue the trial at a single site or at all sites for safety, ethical, compliance or other reasons. If this is necessary, the principle investigator will endeavour to provide advance notification to the site. If the site or trial is suspended or discontinued, the principle investigator will be responsible for ensuring prompt
notification to the METC (CMO Arnhem Nijmegen). Where required by local regulations, the principle investigator will be responsible for informing the METC of trial or site discontinuation. In such cases, all trial data must be returned to the principle investigator at the Radboudumc.
6. SAFETY REPORTING

6.1 Temporary halt for reasons of subject safety
In accordance to section 10, subsection 4, of the WMO, the sponsor will suspend the study if there is sufficient ground that continuation of the study will jeopardise subject health or safety. The sponsor will notify the accredited METC without undue delay of a temporary halt including the reason for such an action. The study will be suspended pending a further positive decision by the accredited METC. The investigator will take care that all subjects are kept informed.

6.2 AEs, SAEs and SUSARs

6.2.1 Adverse events (AEs)
Adverse events are defined as any undesirable experience occurring to a subject during the study, whether or not considered related to Impryl®. All adverse events reported by the subject or observed by the investigator or his staff will be recorded.

6.2.2 Serious adverse events (SAEs)
A serious adverse event is any untoward medical occurrence or effect that
- results in death;
- is life threatening (at the time of the event);
- requires hospitalisation or prolongation of existing inpatients’ hospitalisation;
- results in persistent or significant disability or incapacity;
- is a congenital anomaly or birth defect; or
- any other important medical event that did not result in any of the outcomes listed above due to medical or surgical intervention but could have been based upon appropriate judgement by the investigator.

An elective hospital admission will not be considered as a serious adverse event.

The investigator will report all SAEs to the sponsor without undue delay after obtaining knowledge of the events.

The sponsor will report the SAEs through the web portal ToetsingOnline to the accredited METC that approved the protocol, within 7 days of first knowledge for SAEs that result in death or are life threatening followed by a period of maximum of 8 days to complete the initial preliminary report. All other SAEs will be reported within a period of maximum 15 days after the sponsor has first knowledge of the serious adverse events.
6.2.3 Suspected unexpected serious adverse reactions (SUSARs)

Adverse reactions are all untoward and unintended responses to the food supplement or placebo related to any dose administered.

Unexpected adverse reactions are SUSARs if the following three conditions are met:
1. the event must be serious (see chapter 9.2.2);
2. there must be a certain degree of probability that the event is a harmful and an undesirable reaction to the medicinal product under investigation, regardless of the administered dose;
3. the adverse reaction must be unexpected, that is to say, the nature and severity of the adverse reaction are not in agreement with the product information as recorded in:
   - Summary of Product Characteristics (SPC) for an authorised medicinal product;
   - Investigator’s Brochure for an unauthorised medicinal product.

The sponsor will report expedited the following SUSARs through the web portal ToetsingOnline to the METC:
- SUSARs that have arisen in the clinical trial that was assessed by the METC;
- SUSARs that have arisen in other clinical trials of the same sponsor and with the same medicinal product, and that could have consequences for the safety of the subjects involved in the clinical trial that was assessed by the METC.

The remaining SUSARs are recorded in an overview list (line-listing) that will be submitted once every half year to the METC. This line-listing provides an overview of all SUSARs from the study medicine, accompanied by a brief report highlighting the main points of concern.

The expedited reporting of SUSARs through the web portal Eudravigilance or ToetsingOnline is sufficient as notification to the competent authority.

The sponsor will report expedited all SUSARs to the competent authorities in other Member States, according to the requirements of the Member States.

The expedited reporting will occur not later than 15 days after the sponsor has first knowledge of the adverse reactions. For fatal or life threatening cases the term will be maximal 7 days for a preliminary report with another 8 days for completion of the report.
6.3 Annual safety report

In addition to the expedited reporting of SUSARs, the sponsor will submit, once a year throughout the clinical trial, a safety report to the accredited METC, competent authority, and competent authorities of the concerned Member States.
This safety report consists of:
- a list of all suspected (unexpected or expected) serious adverse reactions, along with an aggregated summary table of all reported serious adverse reactions, ordered by organ system, per study;
- a report concerning the safety of the subjects, consisting of a complete safety analysis and an evaluation of the balance between the efficacy and the harmfulness of the medicine under investigation.

6.4 Follow-up of adverse events

There will be no follow-up of adverse events. There are no adverse events reported in previous use of Impryl. Therefore these are not expected. However, all SAEs and SUSARs will be followed until they have abated, or until a stable situation has been reached. Depending on the event, follow up may require additional tests or medical procedures as indicated, and/or referral to the general physician or a medical specialist. SAEs need to be reported till end of study within the Netherlands, as defined in the protocol.

6.5 Data Safety Monitoring Board (DSMB) / Safety Committee

Due to the known safety of Impryl®, we do have the opinion that establishing a DSMB is not necessary.
7. STATISTICAL ANALYSIS

All data will be analyzed on an intention-to-treat basis. Data of patients who are lost to follow-up, will be included in their randomised group as far as possible. In addition, a per-protocol analysis will be performed for the primary outcome and the secondary outcomes of overall pregnancy number, ongoing pregnancies ≥20 weeks of gestation, time to pregnancy, number of miscarriages and live birth rate.

Descriptive statistics will be calculated to check for major dissimilarities between study groups with respect to baseline information. Baseline data will be described quantitatively. For continuous variables, we will examine the distribution of the observations, and if normally distributed we will summarise them as means with standard deviations (SDs). If they are not normally distributed, then medians and inter-quartile ranges (IQRs) will be reported. For dichotomous data, we will provide counts and proportions (or percentages).

The primary outcome variable ‘ongoing pregnancy’ will be assessed by estimating the ongoing pregnancy percentages overall, and separately for the three strata (i.e. EM, IUI, IVF/ICSI). Differences in pregnancy percentages between the experimental and control group, and the corresponding 95% confidence intervals will be estimated using a fixed effects binomial model with an identity link, including intervention, fertility treatment, centre and female age (centered). If this model does not converge, a logit link will be used.

Time to ongoing pregnancy will be evaluated by the Kaplan-Meier approach; differences between the two arms will be tested with the log-rank test, adjusted for stratum. The other secondary outcomes (overall pregnancy number, number of miscarriages, number of ongoing pregnancies ≥20 weeks of gestation, live birth rate) will be evaluated similarly to the primary outcome. Changes in semen analysis will be assessed either with a fixed effects linear model, with the same covariates as mentioned above, or with a non-parametric method, whatever is applicable. Adverse events will be summarized.

The per-protocol population will consist of all randomised patients without any major deviation from the protocol. A major protocol deviation is defined as:

- Use of other nutritional supplements
- Intake of study medication of less than 75% of the prescribed amount

Participants will be asked by automatic email to report in Castor their actual compliance to the intervention by taking note of total amount of consumed study medication (used
boxes and tablets). Patients will also be asked to report about major changes of their lifestyle occurring during the study period (see page 22).

The results will be extracted from Castor. If there are missing data this will be mentioned along with the reason.

7.1 **Interim analysis**

Given the low risk on adverse events of a nutritional supplement, there are no planned interim analyses.
8. ETHICAL CONSIDERATIONS

8.1 Regulation statement
The study will be conducted according to the principles of the Declaration of Helsinki as amended most recently by the 64th WMA General Assembly, Fortaleza, Brazil, October 2013 and in accordance with the Medical Research Involving Human Subjects Act (WMO).

8.2 Recruitment and consent
Potential subjects will be informed by the treating physician about the study. All subjects will be handed an PIF at their intake consultation. The information letter also contains contact information of the coordinating investigator. If requested the (potential) subject could also receive additional information from the coordinating investigator (R.M Smits). Only after counselling and reading the additional information the (potential) subject will be asked for their informed consent. A consent form must be signed by both the couple as the physician who provided the information. Couples will receive the information preferably at or before (together with appointment letter) their first consultation. The following consultation the subject will be asked whether he will or will not participate. The information letter and informed consent are attached.

8.3 Objection by minors or incapacitated subjects
Not applicable.

8.4 Benefits and risks assessment, group relatedness
As this study compares a food supplement with placebo, it will not impose extra risk on participants. Infertility is a common problem which affects many couples. Therefore research in order to optimize treatment is imperative.

8.5 Compensation for injury
The sponsor/investigator has a liability insurance which is in accordance with article 7 of the WMO. The sponsor (also) has an insurance which is in accordance with the legal requirements in the Netherlands (Article 7 WMO). This insurance provides cover for damage to research subjects through injury or death caused by the study. The insurance applies to the damage that becomes apparent during the study or within 4 years after the end of the study.

8.6 Incentives
Subject will receive no special incentives or compensation.
9. ADMINISTRATIVE ASPECTS, MONITORING AND PUBLICATION

9.1 Handling and storage of data and documents
Data will be collected in an online registration system (Castor) by the coordinating investigator or research nurses. Data handling will be done anonymously, with the patient code only available to the local investigator and the research nurse working in the local centre. The data will be preserved for the duration of 15 years. The handling of personal data complies with the Dutch Personal Data Protection Act (in Dutch: De Wet Bescherming Persoonsgegevens, WBP).

9.2 Monitoring and Quality Assurance
Monitoring will be performed in compliance with Good Clinical Practice (GCP) and other rules and regulations in order to achieve high quality research and secure patient safety.

9.3 Amendments
A ‘substantial amendment’ is defined as an amendment to the terms of the METC application, or to the protocol or any other supporting documentation, that is likely to affect to a significant degree:
- the safety or physical or mental integrity of the subjects of the trial;
- the scientific value of the trial;
- the conduct or management of the trial; or
- the quality or safety of any intervention used in the trial.

All substantial amendments will be notified to the METC and to the competent authority. Non-substantial amendments will not be notified to the accredited METC and the competent authority, but will be recorded and filed by the sponsor.

9.4 Annual progress report
The sponsor/investigator will submit a summary of the progress of the trial to the accredited METC once a year. Information will be provided on the date of inclusion of the first subject, numbers of subjects included and numbers of subjects that have completed the trial, serious adverse events/serious adverse reactions, other problems, and amendments.

9.5 Temporary halt and (prematurely) end of study report
The sponsor will notify the accredited METC and the competent authority of the end of the study within a period of 90 days. The end of the study is defined as the last patient’s last visit, in case of not achieving a pregnancy this will be a telephonic consultation.
The sponsor will notify the METC immediately of a temporary halt of the study, including the reason of such an action.

In case the study is ended prematurely, the sponsor will notify the accredited METC and the competent authority within 15 days, including the reasons for the premature termination.

Within one year after the end of the study, the investigator/sponsor will submit a final study report with the results of the study, including any publications/abstracts of the study, to the accredited METC and the Competent Authority.

9.6 Public disclosure and publication policy
The results will be disclosed unreservedly. The sponsor did not provide the investigators with any restrictions.
10. STRUCTURED RISK ANALYSIS
   Not applicable.
11. REFERENCES